Table 1. Participant demographic characteristics and baseline parasitic infection prevalence by treatment group.
| DA | IDA | Total | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| n | % | (95% CI) | n | % | (95% CI) | n | % | (95% CI) | ||
| Enrolment | Total population | 1616 | 2994 | 4610 | ||||||
| Total consented | 1293 | 80.0 | 2519 | 84.1 | 3812 | 82.7 | ||||
| Sex | Male | 673 | 52.0 | (49.7–54.4) | 1293 | 51.3 | (49.4–53.2) | 1966 | 51.6 | (50.1–53.1) |
| Female | 620 | 48.0 | (45.6–50.3) | 1226 | 48.7 | (46.8–50.6) | 1846 | 48.4 | (46.9–49.9) | |
| Age (years) | Median (IQR) | 27 | (10–48) | 24 | (10–46) | 25 | (10–47) | |||
| <2 | 38 | 2.9 | (2.1–4.0) | 55 | 2.2 | (1.5–3.1) | 93 | 2.4 | (1.9–3.1) | |
| 2–4 | 80 | 6.2 | (5.3–7.3) | 168 | 6.7 | (5.6–7.9) | 248 | 6.5 | (5.7–7.4) | |
| 5–9 | 182 | 14.1 | (11.4–17.3) | 359 | 14.3 | (12.3–16.5) | 541 | 14.2 | (12.6–16.0) | |
| 10–14 | 172 | 13.3 | (10.6–16.6) | 359 | 14.3 | (12.2–16.6) | 531 | 13.9 | (12.3–15.8) | |
| 15–24 | 134 | 10.4 | (8.2–13.0) | 328 | 13.0 | (7.6–21.4) | 462 | 12.1 | (8.2–17.5) | |
| 25–34 | 154 | 11.9 | (9.3–15.1) | 264 | 10.5 | (9.2–11.9) | 418 | 11.0 | (9.7–12.3) | |
| 35–49 | 236 | 18.3 | (15.8–21.0) | 449 | 17.8 | (15.5–20.4) | 685 | 18.0 | (16.2–19.9) | |
| 50–64 | 207 | 16.0 | (12.7–20.0) | 358 | 14.2 | (12.0–16.8) | 565 | 14.8 | (13.0–16.9) | |
| ≥65 | 90 | 7.0 | (5.8–8.3) | 179 | 7.1 | (5.6–8.9) | 269 | 7.1 | (6.0–8.3) | |
| LF | Total assessed CFA | 1239 | 2420 | 3659 | ||||||
| Total CFA positive | 186 | 15.0 | (8.8–24.4) | 330 | 13.6 | (10.0–18.3) | 516 | 14.1 | (11.3–17.5) | |
| CFA1—weak positive | 64 | 5.2 | (3.7–7.2) | 107 | 4.4 | (3.2–6.1) | 171 | 4.7 | (3.8–5.8) | |
| CFA2—medium positive | 59 | 4.8 | (2.4–9.4) | 98 | 4.1 | (3.0–5.4) | 157 | 4.3 | (3.3–5.5) | |
| CFA3—strong positive | 63 | 5.1 | (2.1–11.6) | 125 | 5.2 | (3.4–7.8) | 188 | 5.1 | (3.6–7.4) | |
| LF | Microfilariae positivea | 47 | 3.8 | (1.5–9.1) | 93 | 3.9 | (2.6–5.8) | 140 | 3.8 | (2.6–5.6) |
| Geometric mean density Mf/ml | 239 | (149–383) | 183 | (128–260) | 200 | (151–264) | ||||
| Scabies | Identifiedb | 176 | 13.6 | (7.9–22.4) | 337 | 13.4 | (9.9–17.9) | 513 | 13.5 | (10.4–17.3) |
| STH | Stool specimen assessed | 268 | 20.7 | 658 | 26.1 | 926 | 24.3 | |||
| Positive microscopy | 35 | 13.1 | (6.3–25.1) | 136 | 20.7 | (13.2–30.9) | 171 | 18.5 | (12.7–26.1) | |
| LF Treatmentc | 1216 | 94.0 | (92.5–95.3) | 2396 | 95.1 | (93.9–96.1) | 3612 | 94.8 | (93.9–95.5) | |
| Any follow-up after LF treatment | 1216 | 100 | - | 2382 | 99.4 | (98.5–99.8) | 3598 | 99.6 | (99.0–99.9) | |
DA: diethylcarbamazine and albendazole; IDA: ivermectin, diethylcarbamazine and albendazole; IQR: interquartile range; LF: lymphatic filariasis; CFA: circulating filarial antigen; STH: soil-transmitted helminths; CI: confidence intervals
a Denominator is equal to total assessed CFA subtracting 22 with smears declined or unreadable (DA N = 1238, IDA N = 2399, Total N = 3637).
b Denominator is equal to total consented for each group.
c Denominator is equal to total consented for each group. Participants received treatment as randomised except 1 in DA received IDA, 123 in IDA received DA.